Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. - Wikidata - wikimedia - TriplyDB

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

http://www.wikidata.org/entity/Q38803271

about

Cabozantinib in the treatment of hepatocellular carcinoma.Triple negative breast cancer: the kiss of death.Modulation of cabozantinib efficacy by the prostate tumor microenvironment.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer

P2860

Q38658285-D9006019-5695-40AE-BEA6-DD23867CDC2B Q38818744-BC14F6E0-361E-4E13-96F5-D106B24D36C2 Q46493299-36FED9CB-B1C8-46F4-BCE9-E0B4BCD13077 Q47214510-F2EC0809-FA1A-4FD7-97E6-19E49E6C9D47 Q47275348-EE798D51-69A3-4D45-B395-DE460BBC3889 Q47861428-4038E859-9C70-4274-97CF-FA751C1DC313 Q49953442-DFB2E9C8-55F2-49CE-954C-AF9B2E0024AF Q55476332-31D5941D-2A8A-48CD-BADF-3A45F20574D9 Q57105411-A0526995-2F58-43F1-B638-922941A29299 Q57172436-DF9C2378-3953-4C04-A05F-40BA87E2DD81

P2860

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

http://www.wikidata.org/entity/Q38803271

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase II and Biomarker Study o ...... gative Breast Cancer Patients.

@en

type

label

Phase II and Biomarker Study o ...... gative Breast Cancer Patients.

@en

prefLabel

Phase II and Biomarker Study o ...... gative Breast Cancer Patients.

@en

P1433

Q38803271-4C89F73B-8C46-4F79-93F7-4A2303F5382D

P1476

Q38803271-4CBEDAAC-5844-4B4E-B9D0-171E69639E92

P2093

Q38803271-0839E69C-28EF-4B27-B8A3-B5963F70F65F

Q38803271-1C688AA8-1AEF-4EE1-A7EA-640B3E90C962

Q38803271-35D10229-BE65-4105-89D4-D0EF38B31E07

Q38803271-3DCBCCCA-2720-4BAA-B524-F4AF8DF726E1

Q38803271-4151B83A-FA62-492C-9906-5499AC4FA2D3

Q38803271-4A553FE9-A6BC-413A-B419-7C172163075D

Q38803271-5F5E5550-7810-4967-842F-2DA05AC3B158

Q38803271-6485A66A-78F7-4B98-9758-2708FE59FB92

Q38803271-7B2AB30A-3675-433D-9648-2902F9A3C998

Q38803271-8A730C6A-9083-40BB-93E8-E748854EF2DD

P2860

Q38803271-0A681677-A186-4D4A-8D72-8D1C0E0EC243

Q38803271-0D20D140-A5D5-44D1-9569-C2D465BA1F48

Q38803271-12F89963-5160-4C78-9E68-1739CA91901B

Q38803271-1A58D5A1-EE27-4C17-8BCE-78513C0F562F

Q38803271-1A784604-4531-425A-A2C4-F063B9C0F4AF

Q38803271-2C3EEC3D-7430-4B1B-91AA-F05622FE5A83

Q38803271-3B649051-20CA-4CA2-ACF1-D9E9D32DF0CD

Q38803271-3C698B98-AA86-4130-9FEC-D30CB4315595

Q38803271-4A537CE9-84B2-4550-8108-1A9279145475

Q38803271-4F62909E-33E0-4544-A228-695FD1185C45

P304

Q38803271-B574304C-24CC-4F30-BE31-A92B7D78D6F6

P31

Q38803271-A98A9E5C-A07B-4A49-9ED4-DFB01B585F22

P356

Q38803271-2DBE7D25-CEB1-48DB-81F8-A5934A4F52FD

P433

Q38803271-192E5508-A6FA-42CE-A4EF-BEFAB1C63651

P478

Q38803271-261EFE3B-B21F-476E-B227-63EC1C43B400

P577

Q38803271-EF521602-4A3B-484E-814C-0B2B04D6C8A7

P698

Q38803271-90F8BB16-7488-458D-A3B8-49F7F651ACF5

P921

Q38803271-2F5A4657-E0D0-4BEF-AA19-9555C2A957B4

P932

Q38803271-B1F1A8FE-6836-4FD0-864F-B80D4F805CC0

P356

THEONCOLOGIST.2016-0229

P1433

P1476

Phase II and Biomarker Study o ...... gative Breast Cancer Patients.

@en

P2093

Beth A Overmoyer

http://www.w3.org/2001/XMLSchema#string

Cloud P Paweletz

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

David R Ziehr

http://www.w3.org/2001/XMLSchema#string

Elena V Ivanova

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Hao Guo

http://www.w3.org/2001/XMLSchema#string

Jane E Brock

http://www.w3.org/2001/XMLSchema#string

Mei R Ng

http://www.w3.org/2001/XMLSchema#string

Michaela J Higgins

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Cancer statistics, 2016

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Cabozantinib in progressive medullary thyroid cancer.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.

Epidemiology of basal-like breast cancer.

P304

25-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2016-0229

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27789775

http://www.w3.org/2001/XMLSchema#string

P921

P932

5313267

http://www.w3.org/2001/XMLSchema#string